Current Treatment Landscape for AL Amyloidosis

Opinion
Video

Jeffrey Zonder, MD, offers an overview of the current treatment landscape for AL amyloidosis.

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Panelists discuss the treatment landscape for light chain (AL) amyloidosis, focusing on targeting plasma cells to reduce toxic light chains. They note challenges in adapting multiple myeloma therapies for amyloidosis due to tolerability issues with certain agents. The primary FDA-approved induction regimen is cyclophosphamide-bortezomib-dexamethasone (CyBorD), which demonstrates effectiveness in reducing misfolded light chains, especially with the addition of the monoclonal antibody daratumumab.

Although the regimen significantly improves organ function, it does not impact early survival rates, particularly for patients at high risk of complications. The discussion highlights the ongoing complexities in treating AL amyloidosis, such as balancing effectiveness and survival outcomes.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Video 10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video 9 - "Additional Second-Line Treatments for HCC"
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Video 8 - "Future Outlook for RET Fusion-Targeted Therapies"
Video 7 - "Impact and Positioning of Tumor Agnostic Approvals"
Related Content